For research use only. Not for therapeutic Use.
U-0521 is the inhibitor of the catechol-O-methyltransferase (COMT). U-0521 has the potential for the research of Parkinson’s disease[1].
U-0521 inhibits RBC COMT activity in a dose-dependent manner with an IC50 of 6 x10-6 M[1].
U-0521 (i.p.; 0-250 mg/kg; 10 min) inhibits COMT activity in a dose-dependent manner. 50% inhibition of enzyme activity is obtained at 90 mg/kg and maximum inhibition of 90% is obtained at 250 mg/kg[1].
| Catalog Number | I012021 |
| CAS Number | 5466-89-7 |
| Synonyms | 1-(3,4-dihydroxyphenyl)-2-methylpropan-1-one |
| Molecular Formula | C10H12O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H12O3/c1-6(2)10(13)7-3-4-8(11)9(12)5-7/h3-6,11-12H,1-2H3 |
| InChIKey | VDQLKIBLTMPAHI-UHFFFAOYSA-N |
| SMILES | CC(C)C(=O)C1=CC(=C(C=C1)O)O |
| Reference | [1]. Reches A, et al. Effect of 3′,4′-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum. Biochem Pharmacol. 1982;31(21):3415-3418. |
